## **Michel Noutsias**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6734010/publications.pdf

Version: 2024-02-01

201385 98622 4,679 106 27 citations h-index papers

g-index 110 110 110 3994 docs citations times ranked citing authors all docs

67

#	Article	IF	Citations
1	Left Atrial Deformation in Heart Failure: A Clinical Update. Current Problems in Cardiology, 2023, 48, 101183.	1.1	1
2	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	1.5	8
3	Simultaneous [18F]fluoride and gadobutrol enhanced coronary positron emission tomography/magnetic resonance imaging for <i>in vivo</i> plaque characterization. European Heart Journal Cardiovascular Imaging, 2022, 23, 1391-1398.	0.5	13
4	Pointing a FINGER at the contribution of lifestyle to cardiovascular events and dementia. European Heart Journal, 2022, 43, 2062-2064.	1.0	3
5	The Emerging Role of Combined Brain/Heart Magnetic Resonance Imaging for the Evaluation of Brain/Heart Interaction in Heart Failure. Journal of Clinical Medicine, 2022, 11, 4009.	1.0	4
6	A proposal for implementation of the chest pain unit model in Greece. Hellenic Journal of Cardiology, 2021, 62, 304-305.	0.4	0
7	Cardiac imaging in cardiotoxicity: a focus on clinical practice. Heart Failure Reviews, 2021, 26, 1175-1187.	1.7	13
8	Dual device closure of a bilobar left atrial appendage with a plug (Watchman 2.5â,,¢ 30Âmm) and a pacifier (Amuletâ,,¢ 20Âmm) device. Hellenic Journal of Cardiology, 2021, 62, 81-83.	0.4	2
9	Cardiac amyloidosis: in search of the ideal diagnostic tool. Herz, 2021, 46, 9-14.	0.4	7
10	Participation in disease management programs and major adverse cardiac events in patients after acute myocardial infarction: a longitudinal study based on registry data. BMC Cardiovascular Disorders, 2021, 21, 18.	0.7	2
11	Vibrational Spectroscopic Investigation of Blood Plasma and Serum by Drop Coating Deposition for Clinical Application. International Journal of Molecular Sciences, 2021, 22, 2191.	1.8	5
12	Heat Shock Protein 70 Is Associated With Cardioversion Outcome and Recurrence of Symptomatic Recent Onset Atrial Fibrillation in Hypertensive Patients. Journal of Cardiovascular Pharmacology, 2021, 77, 360-369.	0.8	4
13	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	1.4	8
14	Clinical ethics case consultation in a university department of cardiology and intensive care: a descriptive evaluation of consultation protocols. BMC Medical Ethics, 2021, 22, 99.	1.0	2
15	Emerging trends in cardiovascular research: HFpEF in the spotlight. A bibliometric analysis of the years 2009-2016. Minerva Medica, 2021, 112, 506-513.	0.3	3
16	In vivo assessment of endothelial permeability of coronary lesions with variable degree of stenosis using an albumin-binding MR probe. International Journal of Cardiovascular Imaging, 2021, 37, 3049-3055.	0.7	3
17	Cardiogenic shock with highly complicated course after influenza A virus infection treated with vva-ECMO and Impella CP (ECMELLA): a case report. BMC Cardiovascular Disorders, 2021, 21, 528.	0.7	3
18	Cardiopulmonary Exercise Test Parameters at Three Months After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Are Associated With Late Clinical Outcome. Heart Lung and Circulation, 2020, 29, 202-210.	0.2	6

#	Article	IF	CITATIONS
19	Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Failure Reviews, 2020, 25, 277-294.	1.7	23
20	Advancements in the diagnostic workup, prognostic evaluation, and treatment of takotsubo syndrome. Heart Failure Reviews, 2020, 25, 757-771.	1.7	11
21	Authorsâ€~ response to the letter on HREV-D-19-00059R-1: Advancements in the diagnostic workup, prognostic evaluation and treatment of Takotsubo syndrome. Heart Failure Reviews, 2020, 25, 887-889.	1.7	1
22	Phosphatidylserine (PS) and phosphatidylglycerol (PG) nanodispersions as potential anti-inflammatory therapeutics: Comparison of in vitro activity and impact of pegylation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 23, 102096.	1.7	19
23	Vibrational spectroscopy as a powerful tool for follow-up immunoadsorption therapy treatment of dilated cardiomyopathy – a case report. Analyst, The, 2020, 145, 486-496.	1.7	7
24	Friedreich's Ataxia: Case series and the Additive Value of Cardiovascular Magnetic Resonance. Journal of Neuromuscular Diseases, 2020, 7, 61-67.	1.1	3
25	The pivotal role of cardiovascular imaging in the identification and risk stratification of non-compaction cardiomyopathy patients. Heart Failure Reviews, 2020, 25, 1007-1015.	1.7	9
26	Acute myocardial ischemia in a patient with coronary-subclavian steal syndrome treated by retrograde percutaneous recanalization of the chronic total occlusion of the left subclavian artery. Hellenic Journal of Cardiology, 2020, 62, 225-227.	0.4	2
27	Diabetes prevalence and outcomes in hospitalized cardiorenal-syndrome patients with and without hyponatremia. BMC Nephrology, 2020, 21, 393.	0.8	2
28	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	1.0	49
29	Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Failure, 2020, 7, 1442-1451.	1.4	26
30	Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders, 2020, 20, 78.	0.7	14
31	Comprehensive multimodality characterization of hemodynamically significant and non-significant coronary lesions using invasive and noninvasive measures. PLoS ONE, 2020, 15, e0228292.	1.1	2
32	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	1.2	42
33	Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Journal of Clinical Medicine Research, 2020, 12, 780-786.	0.6	24
34	Meta-analysis confirms improvement of hospitalizations and all-cause mortality of transcatheter mitral valve repair in functional mitral regurgitation. European Heart Journal, 2020, 41, .	1.0	0
35	Title is missing!. , 2020, 15, e0228292.		0
36	Title is missing!. , 2020, 15, e0228292.		0

#	Article	IF	Citations
37	Title is missing!. , 2020, 15, e0228292.		О
38	Title is missing!. , 2020, 15, e0228292.		0
39	Systematic Review of PCR Proof of Parvovirus B19 Genomes in Endomyocardial Biopsies of Patients Presenting with Myocarditis or Dilated Cardiomyopathy. Viruses, 2019, 11, 566.	1.5	11
40	Prognostic Risk Stratification in Left Ventricular Noncompaction: Still a Long Way to Go. Cardiology, 2019, 142, 220-222.	0.6	2
41	High Prevalence of Proarrhythmic Events in Patients With History of Atrial Fibrillation Undergoing a Rhythm Control Strategy: A Retrospective Study. Journal of Clinical Medicine Research, 2019, 11, 345-352.	0.6	6
42	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
43	Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovascular Disorders, 2019, 19, 207.	0.7	27
44	Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors. Heart Failure Reviews, 2019, 24, 977-987.	1.7	11
45	Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment. Heart Failure Reviews, 2019, 24, 439-459.	1.7	48
46	Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases. Heart Failure Reviews, 2019, 24, 489-498.	1.7	12
47	Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Failure Reviews, 2019, 24, 521-533.	1.7	23
48	<p>Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany</p> . Vascular Health and Risk Management, 2019, Volume 15, 477-483.	1.0	10
49	The differential statin effect on cytokine production of monocytes or macrophages is mediated by differential geranylgeranylation-dependent Rac1 activation. Cell Death and Disease, 2019, 10, 880.	2.7	26
50	Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy. Heart Failure Reviews, 2019, 24, 359-366.	1.7	10
51	Noninvasive Imaging of Endothelial Damage in Patients With Different HbA1c Levels: A Proof-of-Concept Study. Diabetes, 2019, 68, 387-394.	0.3	5
52	Acute heart failure. Herz, 2019, 44, 53-55.	0.4	5
53	Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction. Herz, 2019, 44, 425-432.	0.4	24
54	Cognitive performance of patients with chronic heart failure on sacubitril/valsartan. Herz, 2019, 44, 534-540.	0.4	16

#	Article	IF	CITATIONS
55	In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization. Herz, 2019, 44, 651-658.	0.4	7
56	Speckle tracking imaging in hypertrophic cardiomyopathy. Herz, 2019, 44, 265-265.	0.4	0
57	Transplantation in patients with iron overload: is there a place for magnetic resonance imaging?. Heart Failure Reviews, 2018, 23, 173-180.	1.7	1
58	Transcatheter vs. surgical aortic valve replacement and medical treatment. Herz, 2018, 43, 325-337.	0.4	12
59	In-hospital mortality after acute STEMI in patients undergoing primary PCI. Herz, 2018, 43, 741-745.	0.4	14
60	Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovascular Disorders, 2018, 18, 221.	0.7	80
61	Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results. Heart Failure Reviews, 2018, 23, 907-917.	1.7	14
62	Diagnostic approaches forÂpericardial effusions. Herz, 2018, 43, 565-566.	0.4	1
63	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	1.2	224
64	Acquired drug-induced long QTc: new insights coming from a retrospective study. European Journal of Clinical Pharmacology, 2018, 74, 1645-1651.	0.8	5
65	Illustrating the Sense of a Network Meta-Analysis by Means of Dedicated Plots: A Way for Making It Conceptually Easier and More Immediately Understandable. Journal of Clinical Medicine Research, 2018, 10, 732-735.	0.6	2
66	Biovigilance for the Quality and Safety of Medical Products of Human Origin. Journal of Clinical Medicine Research, 2018, 10, 857-867.	0.6	1
67	DCB meets DES. Herz, 2017, 42, 696-697.	0.4	2
68	Association between TLR2/TLR4 gene polymorphisms and COPD phenotype in aÂGreek cohort. Herz, 2017, 42, 752-757.	0.4	9
69	Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): The role of 2D speckle-tracking echocardiography. International Journal of Cardiology, 2017, 243, 374-378.	0.8	38
70	Comorbidity "depression―in heart failure — Potential target of patient education and self-management. BMC Cardiovascular Disorders, 2017, 17, 48.	0.7	8
71	Neural cell adhesion molecule expression in dilated cardiomyopathy is associated with intramyocardial inflammation and hypertrophy. International Journal of Cardiology, 2017, 241, 322-325.	0.8	5
72	Cardiac computed tomography. Herz, 2017, 42, 790-791.	0.4	2

#	Article	IF	CITATIONS
73	The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Failure Reviews, 2017, 22, 743-752.	1.7	40
74	Regulation of cardiomyocyte expression of neural cell adhesion molecule in adult cardiomyopathies â€" Further investigations are pertinent. International Journal of Cardiology, 2017, 249, 333.	0.8	1
75	Takotsubo syndrome – adding pieces to a complex puzzle. BMC Cardiovascular Disorders, 2017, 17, 296.	0.7	2
76	Giant cell myocarditis: still a conundrum. The need for a worldwide registry. European Journal of Heart Failure, 2016, 18, 1459-1461.	2.9	11
77	ZellulÃ <b>¤</b> Immunmechanismen bei Myokarditis. Herz, 2012, 37, 830-835.	0.4	4
78	Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. European Journal of Heart Failure, 2011, 13, 611-618.	2.9	75
79	Biomarkers in Inflammatory and Noninflammatory Cardiomyopathy. Herz, 2009, 34, 614-623.	0.4	8
80	Adaptive immune responses against parvovirus B19 in patients with myocardial disease. Journal of Clinical Virology, 2009, 44, 27-32.	1.6	26
81	Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Molecular Biology, 2008, 9, 3.	3.0	60
82	Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. Journal of Medical Virology, 2008, 80, 1243-1251.	2.5	67
83	Giant-cell myocarditis in a patient presenting with dilated cardiomyopathy and ventricular tachycardias treated by immunosuppression: A case report. International Journal of Cardiology, 2008, 128, e58-e59.	0.8	11
84	Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach. Circulation, 2008, 118, 1722-1728.	1.6	223
85	Suspected Chronic Myocarditis at Cardiac MR: Diagnostic Accuracy and Association with Immunohistologically Detected Inflammation and Viral Persistence. Radiology, 2008, 246, 401-409.	3.6	250
86	NS1 Specific CD8+ T-Cells with Effector Function and TRBV11 Dominance in a Patient with Parvovirus B19 Associated Inflammatory Cardiomyopathy. PLoS ONE, 2008, 3, e2361.	1.1	25
87	Immunohistological detection of Parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. Medical Science Monitor, 2008, 14, CR333-338.	0.5	15
88	Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Medical Science Monitor, 2008, 14, CR589-97.	0.5	17
89	Parvovirus B19–Associated Active Myocarditis With Biventricular Thrombi Results of Endomyocardial Biopsy Investigations and Cardiac Magnetic Resonance Imaging. Circulation, 2007, 115, e378-80.	1.6	13
90	102 Immunohistological detection of parvovirus B19 VP1- and VP2-capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. European Journal of Heart Failure, Supplement, 2007, 6, 24-24.	0.2	1

#	Article	IF	CITATIONS
91	Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin- $1^2$ and MMP-8 expression and a modulated immune response. European Journal of Heart Failure, 2005, 7, 444-452.	2.9	71
92	High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With "ldiopathic―Left Ventricular Dysfunction. Circulation, 2005, 111, 887-893.	1.6	630
93	High Prevalence of Cardiac Parvovirus B19 Infection in Patients With Isolated Left Ventricular Diastolic Dysfunction. Circulation, 2005, 111, 879-886.	1.6	232
94	Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction. Circulation, 2005, 112, 1965-1970.	1.6	506
95	sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. International Journal of Cardiology, 2003, 91, 153-161.	0.8	32
96	Interferon- $\hat{l}^2$ Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction. Circulation, 2003, 107, 2793-2798.	1.6	472
97	Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy. European Journal of Heart Failure, 2003, 5, 469-479.	2.9	27
98	Advances in the immunohistological diagnosis of inflammatory cardiomyopathy. European Heart Journal Supplements, 2002, 4, 154-162.	0.0	12
99	Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Medical Science Monitor, 2002, 8, MT59-71.	0.5	29
100	Phenotypic characterization of infiltrates in dilated cardiomyopathy - diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Medical Science Monitor, 2002, 8, CR478-87.	0.5	28
101	Human Coxsackie-Adenovirus Receptor Is Colocalized With Integrins $\hat{l}_{\pm}$ <sub>v</sub> $\hat{l}^2$ <sub>3</sub> and $\hat{l}_{\pm}$ <sub>v</sub> $\hat{l}^2$ <sub>5</sub> on the Cardiomyocyte Sarcolemma and Upregulated in Dilated Cardiomyopathy. Circulation, 2001, 104, 275-280.	1.6	190
102	Expression of Cell Adhesion Molecules in Dilated Cardiomyopathy. Circulation, 1999, 99, 2124-2131.	1.6	185
103	Cell-Mediated Cytotoxicity in Hearts With Dilated Cardiomyopathy: Correlation With Interstitial Fibrosis and Foci of Activated T Lymphocytes. Journal of the American College of Cardiology, 1997, 29, 429-434.	1.2	55
104	Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy Heart, 1996, 75, 295-300.	1.2	210
105	Immunohistochemistry in dilated cardiomyopathy. European Heart Journal, 1995, 16, 100-106.	1.0	56
106	Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. Journal of Cardiac Failure, 1994, 1, 13-25.	0.7	31